Annual International Exhibition

Kibur Medical Presents Preliminary Clinical Data on Intratumoral Microdosing of High Grade Gliomas at the American Academy of Cancer Research in Orlando, FL

Retrieved on: 
Thursday, April 13, 2023
AACR, Annual International Exhibition, Booth, American Academy, Biomarker, CIA transnational anti-crime and anti-drug activities, Medicine, Poster, FDA, Glioma, Pharmaceutical industry, Patient

BOSTON, April 13, 2023 /PRNewswire-PRWeb/ -- Kibur Medical Inc., a Boston, MA - based company with a vision to close the translational gap in next generation cancer therapies, will present a poster at the upcoming American Academy of Cancer Research (AACR) annual meeting in April describing a recent clinical application of the Kibur technology. Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific mono- and combination therapies. This deep molecular profiling of the drug-tumor response identifies biomarkers of drug activity and enables prediction of drug response. The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in tumor models.

Key Points: 
  • Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific mono- and combination therapies.
  • This deep molecular profiling of the drug-tumor response identifies biomarkers of drug activity and enables prediction of drug response.
  • The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in tumor models.
  • "Our recent clinical data presented at AACR demonstrates that our technology can analyze multiple chemotherapies in combination in high grade gliomas."

Kibur Medical Presents a Rational Approach to Identify Novel Combinations as Potential Immuno-oncology Therapies at the American Academy of Cancer Research in Orlando, FL

Retrieved on: 
Thursday, April 6, 2023
Charles River Laboratories, AACR, Kidney cancer, CDX, Syngenic, GEMM, Annual International Exhibition, Booth, American Academy, Gordon Mills, PDX, Spatial analysis, Oregon Health Plan, Brigham, Drug combination, Northwestern Health Sciences University, Poster, Hospital, FDA, Tumor microenvironment, Oregon Health & Science University, Breast cancer, Pharmaceutical industry

BOSTON, April 6, 2023 /PRNewswire-PRWeb/ -- Kibur Medical Inc., a Boston, MA - based company with a vision to close the translational gap in next generation cancer therapies, will present two posters at the upcoming American Academy of Cancer Research (AACR) annual meeting in April describing immune-oncology applications of the Kibur technology. Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific combination therapies. The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in CDX, syngeneic, xenograft, GEMM & PDX tumor models.

Key Points: 
  • Their innovative, tumor-implanted, drug-eluting microdevice evaluates up to twenty different compounds in vivo, to assess patient-specific combination therapies.
  • The proprietary FDA approved-technology enables evidenced-based analyses of Phase 0 first in human studies and pre-clinical studies in CDX, syngeneic, xenograft, GEMM & PDX tumor models.
  • "This work furthers our mission to transform cancer care and advance precision medicine for better patient outcomes."
  • Following the AACR annual meeting, Kibur is both sponsoring and hosting panel sessions at the 4th Annual International Phase-0/Microdosing Stakeholder Meeting on April 24th in Boston.